3/16/2023 8:10:42 AM
UroGen Pharma Q4 Net Loss $28.2 Mln Or $1.22/shr Vs Loss
$28.5 Mln Or $1.27/shr Prior Year
3/6/2023 8:06:45 AM
UroGen Pharma Announces Grants Of Inducement Restricted Stock Units To 7 New Employees
1/11/2023 8:15:55 AM
UroGen : JELMYTO Review Results Reinforces Efficacy & Safety In Patients With Low-Grade Upper Tract Urothelial Cancer
12/19/2022 8:11:30 AM
UroGen Completes Enrollment Of Phase 3 Trial For UGN-102 In Non-Muscle Invasive Bladder Cancer
12/1/2022 7:35:16 PM
UroGen : Phase 3 Trial Data Shows JELMYTO Provides Effective
and Durable Kidney-sparing Treatment Option
11/10/2022 8:07:46 AM
UroGen Pharma Q3 Net Loss Of $25.8 Mln Or $1.13/shr Vs Loss
$30.2 Mln Or $1.35/shr Prior Year
11/9/2022 8:05:36 AM
UroGen Appoints Dan Wildman To Board
9/28/2022 8:06:47 AM
FDA Authorizes Extension Of In-Use Period For UroGen Pharma's JELMYTO Admixture To 96 Hours
9/12/2022 8:05:44 AM
UroGen Appoints Leana Wen To Board
8/11/2022 8:11:57 AM
UroGen Pharma Q2 Net Loss $26.7 Mln Or $1.18/shr Vs Loss $26.2 Mln Or $1.17/shr Prior Year
5/10/2022 9:08:57 AM
UroGen Pharma Q1 Net Loss Of $28.4 Mln Or $1.25/shr Vs
$25.9 Mln Or $1.17/shr Prior Year
3/29/2022 8:11:02 AM
UroGen: FDA Clears IND Application For Immunotherapy UGN-301 Intravesical Solution In Recurrent NMIBC
3/21/2022 8:10:28 AM
UroGen Pharma Q4 Net Loss $28.5 Mln Or $1.27/Shr Vs Loss $30.5 Mln Or $1.38/Shr Last Year
3/1/2022 8:13:37 AM
UroGen Submits IND Supporting Phase 1 Study Of UGN-301 Intravesical Solution In Non-Muscle Invasive Bladder Cancer